These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1919 related articles for article (PubMed ID: 28043904)

  • 21. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.
    Roskams T
    Oncogene; 2006 Jun; 25(27):3818-22. PubMed ID: 16799623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 23. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tricellulin expression and its prognostic significance in primary liver carcinomas.
    Somorácz A; Korompay A; Törzsök P; Patonai A; Erdélyi-Belle B; Lotz G; Schaff Z; Kiss A
    Pathol Oncol Res; 2014 Oct; 20(4):755-64. PubMed ID: 24652413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
    Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
    Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
    Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
    Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
    Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
    Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
    Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for the examination of specimens from patients with hepatocellular carcinoma and cholangiocarcinoma, including intrahepatic bile ducts. Cancer Committee of the College of American Pathologists.
    Ruby SG
    Arch Pathol Lab Med; 2000 Jan; 124(1):41-5. PubMed ID: 10629130
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 96.